HCW Biologics Inc. filed a preliminary proxy statement on November 18, 2026, calling a Special Meeting of Stockholders for January 26, 2027, to seek approval for the issuance of common stock warrants tied to two private placement financings completed earlier in 2026.

Key Highlights

  • Special Meeting date: January 26, 2027 at 10:00 a.m. Eastern Time, to be held as a fully virtual meeting.
  • July placement warrants: Stockholders will vote on approving common warrants exercisable for up to 618,682 shares of Common Stock at $2.585 per share, tied to a $1.6 million private placement completed July 29, 2026.
  • September placement warrants: A second proposal covers common warrants exercisable for up to 903,614 shares of Common Stock at $1.660 per share, tied to a $1.5 million private placement completed September 23, 2026.
  • Nasdaq 20% Rule: Both proposals are required under Nasdaq Listing Rule 5635(d), which mandates stockholder approval before the company may issue 20% or more of outstanding Common Stock.
  • Prior meeting lapsed: Proposal One was previously presented at a special meeting held November 17, 2026, but a quorum was not present and the proposal was not acted upon.
  • Record date: December 15, 2026 is the record date; proxy materials are expected to be mailed on or about December 17, 2026.
  • Board recommendation: The Board recommends a vote FOR both Proposals One and Two.

HCW Biologics Calls January 2027 Meeting to Ratify 2026 Financing Warrants

HCW Biologics Inc. (NASDAQ:HCWB), a biopharmaceutical company headquartered at 2929 N. Commerce Parkway, Miramar, Florida 33025, filed this preliminary proxy statement to solicit stockholder approval for warrant issuances arising from two separate private placement transactions. The company, led by Founder and Chief Executive Officer Hing C. Wong, Ph.D., disclosed that it is obligated to continue seeking stockholder approval until such approval is obtained, as specified in the applicable financing documents.

According to the filing, the July 29, 2026 transaction raised $1.6 million, with investors receiving the right to receive, subject to stockholder approval, common stock warrants exercisable to purchase up to 618,682 shares of Common Stock at an exercise price of $2.585 per share. The September 23, 2026 transaction raised $1.5 million, with investors receiving the right to receive, subject to stockholder approval, common stock warrants exercisable to purchase up to 903,614 shares of Common Stock at an exercise price of $1.660 per share. Both sets of warrants are described in the filing as "July Common Warrants" and "September Common Warrants," respectively.

The filing notes that both proposals are presented under Nasdaq Listing Rule 5635(d), commonly referred to as the "20% Rule," which requires stockholder approval before a Nasdaq-listed company may issue shares equal to 20% or more of its outstanding Common Stock in connection with certain transactions. The proxy statement discloses that Proposal One previously failed to receive a quorum at the November 17, 2026 special meeting, necessitating this follow-on solicitation. Each share of Common Stock held as of the December 15, 2026 record date represents one vote.

What Was Disclosed

HCW Biologics filed a preliminary proxy statement calling a January 26, 2027 special stockholder meeting. The two proposals seek approval of common stock warrants from a $1.6 million July 2026 private placement and a $1.5 million September 2026 private placement, both requiring a Nasdaq Rule 5635(d) stockholder vote.